Dataset Information


MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury.

ABSTRACT: Nucleotide oligomerization domain (NOD)-like receptor protein-3 (NLRP3) inflammasome may intimately contribute to sustaining damage after traumatic brain injury (TBI). This study aims to examine whether specific modulation of NLPR3 inflammasome by MCC950, a novel selective NLRP3 inhibitor, confers protection after experimental TBI. Unilateral cortical impact injury was induced in young adult C57BL/6 mice. MCC950 (50 mg/kg, intraperitoneally) or saline was administration at 1 and 3 h post-TBI. Animals were tested for neurological function and then sacrificed at 24 or 72 h post-TBI. Immunoblotting and histological analysis were performed to identify markers of NLRP3 inflammasome and proapoptotic activity in pericontusional areas of the brains at 24 or 72 h post-TBI. MCC950 treatment provided a significant improvement in neurological function and reduced cerebral edema in TBI animals. TBI upregulated NLRP3, apoptosis-associated speck-like adapter protein (ASC), cleaved caspase-1, and interlukein-1β (IL-1β) in the perilesional area. MCC950 efficiently repressed caspase-1 and IL-1β with a transient effect on ASC and NLRP3 post-TBI. MCC950 treatment also provided protection against proapoptotic activation of poly (ADP-ribose) polymerase and caspase-3 associated with TBI. A concurrent inhibition of inflammasome priming was also detectable at the nuclear factor kappa B/p65 and caspase-1 level. Our findings support the implication of NLRP3 inflammasome in the pathogenesis of TBI and further suggests the therapeutic potential of MCC950.


PROVIDER: S-EPMC5962912 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5529650 | BioStudies
| S-EPMC7428617 | BioStudies
1000-01-01 | S-EPMC5550855 | BioStudies
2020-01-01 | S-EPMC7582915 | BioStudies
| S-EPMC7457538 | BioStudies
1000-01-01 | S-EPMC5988655 | BioStudies
| S-EPMC6483075 | BioStudies
2018-01-01 | S-EPMC6264724 | BioStudies
2019-01-01 | S-EPMC7116292 | BioStudies
2020-01-01 | S-EPMC7691250 | BioStudies